Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for gastrointestinal diseases. Founded in 2018 and headquartered in Buffalo Grove, Illinois, Phathom Pharmaceuticals possesses exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium-competitive acid blocker (PCAB). This groundbreaking medication inhibits acid secretion in the stomach and has shown significant clinical benefits, providing rapid, potent, and sustained acid suppression.
Phathom's flagship product, VOQUEZNA® (vonoprazan), is now FDA-approved and available in the U.S. for treating Erosive Esophagitis (Erosive GERD) and relieving associated heartburn in adults. VOQUEZNA is the first new class of acid suppression medication approved in the U.S. in over 30 years, offering a novel mechanism of action distinct from other treatments. Its efficacy, demonstrated in clinical trials, surpasses that of traditional proton pump inhibitors (PPIs), showcasing strong healing rates and durable results.
In addition to treating GERD, Phathom is developing vonoprazan for use in combination with antibiotics to treat Helicobacter pylori (H. pylori) infection. VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® are expected to be commercially available soon, providing comprehensive treatment regimens co-packaged with antibiotics.
Phathom Pharmaceuticals is actively engaged in several key initiatives and collaborations. Recent milestones include the U.S. commercial availability of VOQUEZNA, the completion of Phase 3 trials for Non-Erosive GERD, and the amendment of a term loan facility enhancing financial flexibility. Their innovative approach and dedicated national sales force have driven significant market penetration, with VOQUEZNA now estimated to cover 60 million lives through partnerships with major pharmacy benefit managers.
Phathom is committed to addressing unmet medical needs by offering co-pay assistance programs to ensure accessibility and affordability for patients. They continue to explore new treatment options and expand the indications for vonoprazan through ongoing research and development efforts.
For more information, visit the company’s website at www.phathompharma.com, and follow them on LinkedIn and X (formerly Twitter).
Phathom Pharmaceuticals (Nasdaq: PHAT) announced that its executives, including President and CEO Terrie Curran, will engage in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 11:00 a.m. ET. The company will also hold one-on-one meetings during the virtual conference from September 9-15, 2021. Phathom focuses on developing innovative treatments for gastrointestinal diseases, notably vonoprazan, a potassium competitive acid blocker in late-stage development for acid-related disorders. Recordings will be available for 90 days following the event.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q2 2021 financial results, revealing a net loss of $36.6 million, up from $21.1 million YoY. R&D expenses rose to $21.6 million due to increased clinical trial and CMC costs. General and administrative expenses also climbed to $13.7 million. The company anticipates pivotal Phase 3 data for vonoprazan in erosive esophagitis by October 2021 and Phase 2 data in Q1 2022. Additionally, Phathom is set to submit NDAs for vonoprazan-based regimens for H. pylori in September 2021, with cash reserves of $209.7 million sufficient into Q4 2022.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced the unexpected passing of its chairman and founder, Dr. Tachi Yamada, on August 4, 2021, at his home in Seattle, Washington. The company expressed deep condolences to Dr. Yamada's family, highlighting his significant contributions to both Phathom and the field of gastroenterology. Dr. Yamada was recognized as a transformative figure in his industry. Phathom, specializing in treatments for gastrointestinal diseases, is advancing its late-stage development of vonoprazan, a novel treatment for acid-related disorders.
Phathom Pharmaceuticals (Nasdaq: PHAT) will participate in the virtual BMO Biopharma Spotlight Series on August 12, 2021. Terrie Curran, the company's President and CEO, will be part of the "Innovation in GI" panel discussion at 10:50 a.m. ET. Additionally, Phathom management will engage in one-on-one meetings during the event. An on-demand webcast will be accessible on their website for 30 days post-event. Phathom specializes in developing treatments for gastrointestinal diseases and has in-licensed vonoprazan, a late-stage P-CAB treatment for acid-related disorders.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) has announced that its management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 10:00 a.m. ET. The conference runs from June 1-4, 2021, during which management will also engage in one-on-one meetings. Investors can access a live webcast and archived recording via the Phathom website, available for 90 days post-event. Phathom focuses on developing treatments for gastrointestinal diseases, with exclusive rights to vonoprazan for acid-related disorders.
Phathom Pharmaceuticals (NASDAQ: PHAT) reported a positive Phase 3 trial outcome for vonoprazan in treating H. pylori infections, meeting all primary and secondary endpoints. The FDA granted additional qualified infectious disease product (QIDP) designations to vonoprazan-based therapies. The company is set to submit New Drug Applications (NDAs) in Q4 2021. Despite a net loss of $34.8 million in Q1 2021, cash reserves of $238 million are projected to fund operations through Q4 2022.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced its participation in the Bank of America Securities 2021 Virtual Healthcare Conference on May 13, 2021, at 8:45 a.m. ET. Members of the management team will engage in a fireside chat and conduct one-on-one meetings. Interested parties can access the live webcast and a subsequent recording on Phathom's website, available for 90 days post-event. The company focuses on developing treatments for gastrointestinal diseases, including its late-stage candidate, vonoprazan, a novel potassium competitive acid blocker.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced successful results from its pivotal Phase 3 trial, PHALCON-HP, which tested vonoprazan-based treatment regimens for H. pylori eradication. Both vonoprazan triple therapy (84.7% eradication rate) and dual therapy (78.5%) surpassed the standard lansoprazole triple therapy (78.8%). Phathom plans to submit New Drug Applications (NDA) by Q4 2021. The trial highlighted the need for improved therapies facing rising antibiotic resistance. The safety profile of vonoprazan was comparable to existing treatments, with adverse event rates generally low.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 10:15 a.m. ET. The management team will also hold one-on-one meetings during the event from April 12-15, 2021. For access to the live webcast and archived recording, visit the Phathom website. The company focuses on developing treatments for gastrointestinal diseases and has in-licensed vonoprazan, a potassium competitive acid blocker targeting acid-related disorders.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported its financial results for Q4 and FY 2020, revealing a net loss of $53.7 million in Q4, down from $98 million in Q4 2019, and a total net loss of $129.1 million for the year, improved from $255.1 million in 2019. The company completed patient enrollment in pivotal Phase 3 trials for vonoprazan for erosive esophagitis and H. pylori infections. They raised $89 million in a public offering to fund clinical development. 2021 milestones include expected results from these trials and submission of an NDA for H. pylori.
FAQ
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
What is the market cap of Phathom Pharmaceuticals (PHAT)?
What does Phathom Pharmaceuticals focus on?
What is vonoprazan?
What conditions does VOQUEZNA treat?
What makes VOQUEZNA unique?
Are there other products in development at Phathom?
Where is Phathom Pharmaceuticals headquartered?
When was Phathom Pharmaceuticals incorporated?
What recent financial milestone did Phathom achieve?
How can patients afford VOQUEZNA?
Where can I find more information about Phathom Pharmaceuticals?
